Answers are grounded in this paper and cite their sources.
This review highlights paeoniflorin's protective impact on liver and intestinal diseases, indicating its potential in therapy.
Hepatointestinal diseases seriously reduce the quality of life of affected individuals and pose a heavy burden on the society. Currently, there are some anti-hepatointestinal disease drugs in use; however, they have limitations. Paeoniflorin (PF) is a single terpenoid glycoside extracted from the roots of Paeonia lactiflora Pall. and Paeonia veitchii Lynch. It is a widely prescribed Chinese herbal medicine for the treatment of liver and intestinal diseases and has multipathway and multitarget characteristics. This review aimed to systematically summarize the pharmacological effects of PF on hepatointestinal diseases and its mechanisms of action. Regarding liver disease, PF shows remarkable anti-inflammatory, antioxidant, anti-apoptosis, and bile acid metabolism effects through the regulation of silent information regulator sirtuin 1/farnesol X receptor (FXR), high mobility group box 1/toll-like receptor 4, insulin receptor substrates/protein kinase B (Akt)/glycogen synthase kinase-3 β, and phosphoinositide 3-kinase/Akt signaling pathways. In addition, it plays an anti-fibrosis role through the transforming growth factor (TGF)-β1/Smads and liver X receptors/signal transducer and activator of transcription 3 pathways. PF can prevent the invasion and metastasis of hepatocellular carcinoma cells by inhibiting the expression of the TGF-β1/Smads and mitogen-activated protein kinase/extracellular regulated protein kinases signaling pathways. Regarding intestinal diseases, PF exerts mitochondrial protection and macrophage regulation and has anti-inflammatory and antioxidant effects through the regulation of the muramyl dipeptide/nucleotide-binding oligomerization domain 2, mammalian target of rapamycin/hypoxia inducible factor-1α, and liver kinase B1/AMP-activated protein kinase pathways. In addition, it is involved in liver-intestinal axis interaction through the regulation of FXR, bile acids, and intestinal flora. This review provides a solid foundation for the utilization of PF in hepatointestinal disease treatment. Further research and development of new dosage forms will extend its application in the field of hepatointestinal protection.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: